Phragmites Communis (Lu Gen) Alleviates Hyperuricemia via Xanthine Oxidase Inhibition and Gut-Microbiota-Mediated Metabolite Urate Transporter Regulation

Background: Hyperuricemia (HU) results from excessive uric acid (UA) production/impaired excretion and is associated with gout and renal dysfunction. Gut microbiota dysbiosis may impair intestinal UA excretion, disrupt the gut barrier, and promote inflammation. Traditional Chinese medicine (TCM), with multitarget and microbiota-modulating effects, may offer a therapeutic strategy for HU. In this study, the rhizome of Phragmites communis, a TCM used for clearing heat and promoting diuresis, was investigated. Specifically, we evaluated whether P. communis could alleviate HU by suppressing xanthine oxidase (XOD) and modulating urate transporter expression, thereby reducing UA production while promoting its excretion. Method: The effects of a crude extract of P. communis were investigated with in vitro and in vivo models using molecular, 16S rRNA sequencing, and metabolomic analyses. Results: P. communis significantly decreased serum uric acid (SUA) levels by inhibiting XOD and improving renal and intestinal urate excretion, accompanied by decreased renal and increased intestinal solute carrier family 2 member 9 (SLC2A9) and enhanced ATP-binding cassette subfamily G member 2 (ABCG2) expression, restored gut barrier integrity, and suppressed inflammation. Microbiota analysis revealed enrichment of Ligilactobacillus, Prevotella, and Dubosiella. Fecal metabolomics identified hippuric acid (HA), which correlated with Ligilactobacillus abundance. In vitro, HA enhanced ABCG2, PDZ domain-containing 1 (PDZK1), and SLC2A9 expression. Molecular docking identified feruloylquinic acid (FAQ) as the favorable XOD inhibitor. Conclusions: P. communis exerts anti-hyperuricemic effects by inhibiting UA biosynthesis, promoting UA excretion, modulating gut microbiota, restoring gut barrier integrity, and suppressing inflammation, highlighting its potential as a TCM-based therapeutic intervention for HU.

Authors

Institutions

Publication Details

Journal
Pharmaceuticals
Published
2026-09-17
DOI
https://doi.org/10.3390/ph19091474
Primary Topic
Gout, Hyperuricemia, Uric Acid
Type
article
Field-Weighted Citation Impact
0.00
Controls
|||
ALL TIME
JAN
FEB
MAR
APR
MAY
JUN
JUL
AUG
SEP
article

Phragmites Communis (Lu Gen) Alleviates Hyperuricemia via Xanthine Oxidase Inhibition and Gut-Microbiota-Mediated Metabolite Urate Transporter Regulation

Qidi Xue, Aamir Saleem, Immad Ansari, Ming Li et al.
Pharmaceuticals
Gout, Hyperuricemia, Uric Acid
article

Phragmites Communis (Lu Gen) Alleviates Hyperuricemia via Xanthine Oxidase Inhibition and Gut-Microbiota-Mediated Metabolite Urate Transporter Regulation

Qidi Xue, Aamir Saleem, Immad Ansari, Ming Li, Xiaoqing Wei, Bushra Walayat
article en

Abstract

Background: Hyperuricemia (HU) results from excessive uric acid (UA) production/impaired excretion and is associated with gout and renal dysfunction. Gut microbiota dysbiosis may impair intestinal UA excretion, disrupt the gut barrier, and promote inflammation. Traditional Chinese medicine (TCM), with multitarget and microbiota-modulating effects, may offer a therapeutic strategy for HU. In this study, the rhizome of Phragmites communis, a TCM used for clearing heat and promoting diuresis, was investigated. Specifically, we evaluated whether P. communis could alleviate HU by suppressing xanthine oxidase (XOD) and modulating urate transporter expression, thereby reducing UA production while promoting its excretion. Method: The effects of a crude extract of P. communis were investigated with in vitro and in vivo models using molecular, 16S rRNA sequencing, and metabolomic analyses. Results: P. communis significantly decreased serum uric acid (SUA) levels by inhibiting XOD and improving renal and intestinal urate excretion, accompanied by decreased renal and increased intestinal solute carrier family 2 member 9 (SLC2A9) and enhanced ATP-binding cassette subfamily G member 2 (ABCG2) expression, restored gut barrier integrity, and suppressed inflammation. Microbiota analysis revealed enrichment of Ligilactobacillus, Prevotella, and Dubosiella. Fecal metabolomics identified hippuric acid (HA), which correlated with Ligilactobacillus abundance. In vitro, HA enhanced ABCG2, PDZ domain-containing 1 (PDZK1), and SLC2A9 expression. Molecular docking identified feruloylquinic acid (FAQ) as the favorable XOD inhibitor. Conclusions: P. communis exerts anti-hyperuricemic effects by inhibiting UA biosynthesis, promoting UA excretion, modulating gut microbiota, restoring gut barrier integrity, and suppressing inflammation, highlighting its potential as a TCM-based therapeutic intervention for HU.

PharmaceuticalsVol. 19(9)
Dalian Medical University (CN)
Openalex Percentile: Top 11%
Gout, Hyperuricemia, Uric Acid
AI Navigator

Ask Laika to Summarize, Analyze, and Connect papers live on the map.

Summarize Papers & Methodologies

Extract key findings, datasets, and comparative methods across publications.

Benchmark Rankings & Visual Analytics

Rank top research institutions, authors, funders, topics, and journals by Field-Weighted Citation Impact (FWCI) and paper volume with instant charts.

Connect Distant Disciplines

Bridge topological clusters on the map to find hidden collaborative intersections.